Last reviewed · How we verify

Insulin Degludec 100 UNT/ML [Tresiba]

Merete Bechmann Christensen · FDA-approved active Small molecule

Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.

Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameInsulin Degludec 100 UNT/ML [Tresiba]
SponsorMerete Bechmann Christensen
Drug classLong-acting basal insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin degludec is an ultra-long-acting insulin analog engineered with a 16-carbon fatty acid chain that enables multi-hexamer formation and subcutaneous depot formation, resulting in an exceptionally long half-life of approximately 25 hours and a duration of action exceeding 42 hours. It binds to the human insulin receptor with similar affinity to human insulin, activating downstream signaling pathways that increase glucose uptake in muscle and adipose tissue and inhibit gluconeogenesis in the liver. This extended duration allows for once-daily dosing with a stable, flat pharmacodynamic profile.

Approved indications

Common side effects